GlobeNewswire Inc.··NaArriVent to Showcase EGFR Inhibitor and Dual-Target ADC at 2026 AACR Meeting
ArriVent BioPharma presents preclinical data on firmonertinib and ARR-002 ADC at 2026 AACR Annual Meeting, highlighting oncology pipeline progress.
AVBPPhase 3 trialNSCLC